無料プレビュー

Novo Nordisk A/S (NVO) · New York Stock Exchange

プロフィール

Novo Nordisk A/S is a global healthcare company that discovers, develops, manufactures and markets pharmaceutical products primarily focused on obesity and diabetes care and treatments for certain rare diseases. It offers prescription medicines including GLP-1 receptor agonists for obesity and diabetes, modern and human insulins, growth hormone and haemophilia therapies, and related delivery devices and services. The company operates through two principal business segments—Obesity and Diabetes care and Rare disease. Novo Nordisk markets its products worldwide through subsidiaries, distributors

主要指標

株価: $38.18 (-0.21%)
時価総額: 1,695億ドル
PER（今期予想）: 11.4
PBR: 5.1
配当利回り: 4.71%
52週レンジ: $35.12 – $64.16
業種: Healthcare / Drug Manufacturers - General
上場: New York Stock Exchange
構成銘柄: —

比較会社: LLY Eli Lilly and Company、JNJ Johnson & Johnson、ABBV AbbVie Inc.、MRK Merck & Co., Inc.、NVS Novartis AG、AZN AstraZeneca PLC、AMGN Amgen Inc.、GILD Gilead Sciences, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-04 · 更新: 2026-10-09